Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 18/20 | 1.00 |
| ▸ | CA1 | P00915 | 16/20 | 1.00 |
| ▸ | CA9 | Q16790 | 10/20 | 1.00 |
| ▸ | CA4 | P22748 | 7/20 | 1.00 |
| ▸ | CA12 | O43570 | 5/20 | 1.00 |
| ▸ | CA7 | P43166 | 5/20 | 1.00 |
| ▸ | CA6 | P23280 | 4/20 | 1.00 |
| ▸ | CA5A | P35218 | 4/20 | 1.00 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 1.00 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 1.00 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 1.00 |
| ▸ | CA3 | P07451 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CA11 | O75493 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2987404 | 0.98 | CA2 (0.95) | CA2CA1CA9CA4CA12 | |
| SCHEMBL3500987 | 0.98 | CA2 (0.95) | CA2CA1CA9CA4CA12 | |
| SCHEMBL9796194 | 0.84 | CA2 (0.71) | CA2CA1CA9CA4CA12 | |
| SCHEMBL6507990 | 0.78 | CA2 (0.64) | CA2CA1CA9CA4CA12 | |
| SCHEMBL11169964 | 0.78 | CA2 (0.64) | CA2CA1CA9CA4CA12 | |
| SCHEMBL2648743 | 0.78 | CA2 (0.64) | CA2CA1CA9CA4CA12 | |
| SCHEMBL9860007 | 0.75 | CA2 (0.59) | CA2CA1CA9CA4CA12 | |
| SCHEMBL21267685 | 0.75 | CA2 (0.59) | CA2CA1CA9CA4CA12 | |
| SCHEMBL22592813 | 0.73 | CA2 (0.58) | CA2CA1CA9CA4CA12 | |
| SCHEMBL10711085 | 0.73 | CA2 (0.58) | CA2CA1CA9CA4CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 340 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119040975-A | Additive for electroplating copper, preparation method thereof and electroplating liquid | 上海铂仕通新材料科技有限公司 | 2024-11-29 | — | — | CN | claimed |
| CN-118922081-A | Insect, acarina and nematode pest control | 先正达农作物保护股份公司 | 2024-11-08 | — | — | CN | claimed |
| CN-116807675-A | Method for general anesthesia of pandas | 成都大熊猫繁育研究基地 | 2023-09-29 | — | — | CN | claimed |
| CN-116655706-A | Lipid tetravalent platinum derivative composition and preparation method and application thereof | 青岛大学 | 2023-08-29 | — | — | CN | claimed |
| CN-114272247-B | hypoxia/ROS responsive polymer prodrug for blocking pancreatic duct adenocarcinoma innervation by deep penetration | 宁波大学 | 2023-04-25 | — | — | CN | claimed |
| CN-115754054-A | Method for simultaneously detecting concentrations of three oxazolidinone drugs based on liquid chromatography-mass spectrometry | 中国人民解放军总医院 | 2023-03-07 | — | — | CN | claimed |
| CN-115697059-A | Active compound combinations | 拜耳公司 | 2023-02-03 | — | — | CN | claimed |
| CN-110790724-B | Selective carbonic anhydrase inhibitor and synthesis method and application thereof | 中山大学 | 2023-01-31 | — | — | CN | claimed |
| CN-113024617-B | N-aryl sulfonamide-N-beta-D-glucopyranose diamide compounds and application thereof | 沈阳药科大学 | 2022-09-13 | — | — | CN | claimed |
| CN-115003674-A | Use of pyrido [1,2-a ] pyrimidone compounds for the treatment of lymphomas | 正大天晴药业集团股份有限公司 | 2022-09-02 | — | — | CN | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| EP-1697302-A1 | COMPOUNDS FOR DIAGNOSIS, TREATMENT AND PREVENTION OF BONE INJURY AND METABOLIC DISORDERS | University of Louisville Research Foundation (US) | 2006-09-06 | — | — | EP | claimed |
| US-20060183756-A1 | Pyrrazolo-pyrimidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-08-17 | — | — | US | claimed |
| WO-2006084634-A1 | PYRAZOLO-PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-08-17 | — | — | WO | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| WO-2005066114-A1 | COMPOUNDS FOR DIAGNOSIS, TREATMENT AND PREVENTION OF BONE INJURY AND METABOLIC DISORDERS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION (US) | 2005-07-21 | — | — | WO | claimed |
| US-20050143366-A1 | Compounds for diagnosis, treatment and prevention of bone injury and metabolic disorders | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | 2005-06-30 | — | — | US | claimed |
| US-5288735-A | Water soluble carbonic anhydrase inhibitor | TRAGER SEYMOUR F (US) | 1994-02-22 | — | — | US | claimed |
| US-4975446-A | WATER SOLUBLE CARBONIC ANHYDRASE INHIBITOR; 1,3,4-THIADIAZOLE DERIVATIVES | TRAGER SEYMOUR F (US) | 1990-12-04 | — | — | US | claimed |
| US-4562260-A | OXIDATIVE-CHLORINATION IN ACID SOLUTION WITH INORGANIC SALT AND EXCESS CHLORINE AND PURGING EXCESS CHLORINE | UNION CARBIDE CORPORATION (US) | 1985-12-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143366-A1 | Compounds for diagnosis, treatment and prevention of bone injury and metabolic disorders | SOST, BMP2, BMP4 | CA2 1902/4885CA1 2975/4885CA9 1717/4885 |
| US-20060183756-A1 | Pyrrazolo-pyrimidine derivatives | GRM1, GRM2, GRM3 | CA2 2897/4885CA1 3719/4885CA9 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.